[Sofia, Bulgaria] – An innovative study on antibiotic resistance, featuring contributions from Professor Krasimir Kalinov, Head of the Biometrics Team at Comac Medical, offers new hope for treating multidrug-resistant urinary tract infections (UTIs) antibiotic resistance, growing public health concern.
Recently published in Microorganisms MDPI, a peer-reviewed journal, the study assessed the potential of an older antibiotic combination, trimethoprim/sulfamethoxazole (TRS), for treatment of recurrent UTIs caused by Klebsiella pneumoniae, a bacterium known for its resistance to multiple drugs.
This study involved 11 patients with persistent UTIs who had failed multiple antibiotic treatments. Researchers implemented a structured approach, beginning with tailored intravenous antibiotics, followed by a long-term TRS regimen. The results showed that TRS, when carefully administered, could be a cost-effective alternative for combatting multidrug-resistant UTIs as all the patients experienced microbial eradication and were successfully treated.
Comac Medical extends our sincerest congratulations to the entire research team for their outstanding work and dedication. In particular, Professor Kalinov’s valuable contributions to this study demonstrate Comac Medical’s commitment to research excellence and innovation in clinical development.
Click here to read the full publication.
About Comac Medical
Comac Medical continues to expand its expertise in urology research, with a growing portfolio of studies to improving treatments for urological conditions. Our commitment to excellence and innovation reinforces our place in the forefront of clinical development, providing high-quality research that makes a real impact on patient care worldwide.
